Phase 1 study to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of AJM300 in healthy male subjects - randomised, double-blind, controlled trial
Latest Information Update: 21 Dec 2021
Price :
$35 *
At a glance
- Drugs Carotegrast (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions
- Sponsors EA Pharma
- 21 Dec 2021 New trial record